1 |
Panaretakis T, Kepp O, Brockmeier U, Tesniere A, Bjorklund AC, Chapman DC, Durchschlag M, Joza N, Pierron G, van Endert P, Yuan J, Zitvogel L, Madeo F, Williams DB, Kroemer G: Mechanisms of pre-apoptotic calreticulin exposure in immunogenic cell death. EMBO J 28;578-590, 2009.
DOI
ScienceOn
|
2 |
Kim JS, Rhee HK, Park HJ, Lee IK, Lee SK, Suh ME, Lee HJ, Ryu CK, Choo HY: Synthesis of 6-chloroisoquinoline- 5,8-diones and pyrido[3,4-b]phenazine-5,12-diones and evaluation of their cytotoxicity and DNA topoisomerase II inhibitory activity. Bioorg Med Chem 15;451-457, 2007.
DOI
ScienceOn
|
3 |
Seo JM, Jin YR, Ryu CK, Kim TJ, Han XH, Hong JT, Yoo HS, Lee CK, Yun YP: JM91, a newly synthesized indoledione derivative, inhibits rat aortic vascular smooth muscle cells proliferation and cell cycle progression through inhibition of ERK1/2 and Akt activations. Biochem Pharmacol 75;1331-1340, 2008.
DOI
ScienceOn
|
4 |
Obeid M, Tesniere A, Ghiringhelli F, Fimia GM, Apetoh L, Perfettini JL, Castedo M, Mignot G, Panaretakis T, Casares N, Métivier D, Larochette N, van Endert P, Ciccosanti F, Piacentini M, Zitvogel L, Kroemer G: Calreticulin exposure dictates the immunogenicity of cancer cell death. Nat Med 13;54-61, 2007.
DOI
ScienceOn
|
5 |
Ko JH, Yeon SW, Ryu JS, Kim TY, Song EH, You HJ, Park RE, Ryu CK: Synthesis and biological evaluation of 5-arylamino- 6-chloro-1H-indazole-4,7-diones as inhibitors of protein kinase B/Akt. Bioorg Med Chem Lett 16;6001-6005, 2006.
DOI
ScienceOn
|
6 |
Chung KH, Hong SY, You HJ, Park RE, Ryu CK: Synthesis and biological evaluation of 5-arylamino-1H-benzo[d]imidazole- 4,7-diones as inhibitor of endothelial cell proliferation. Bioorg Med Chem 14;5795-5801, 2006.
DOI
ScienceOn
|
7 |
Spreafico F, Vecchi A, Colotta F, Montovani A: Cancer chemotherapeutics as immunomodulators. Springer Semin Immunopathol 8;361-374, 1985.
DOI
ScienceOn
|
8 |
Esumi N, Hunt B, Itaya T, Frost P: Reduced tumorigenicity of murine tumor cells secreting gamma-interferon is due to nonspecific host responses and is unrelated to class I major histocompatibility complex expression. Cancer Res 51;1185- 1189, 1991
|
9 |
Janelidze S, Bexell D, Badn W, Darabi A, Smith KE, Fritzell S, Gunnarsson S, Milos P, Bengzon J, Salford LG, Siesjo P, Visse E: Immunizations with IFNgamma secreting tumor cells can eliminate fully established and invasive rat gliomas. J Immunother 32;593-601, 2009.
DOI
ScienceOn
|
10 |
Chan OT, Yang LX: The immunological effects of taxanes. Cancer Immunol Immunother 49;181-185, 2000.
DOI
ScienceOn
|
11 |
North RJ: Cyclophosphamide-facilitated adoptive immunotherapy of an established tumor depends on elimination of tumor-induced suppressor T cells. J Exp Med 155;1063-1074, 1982.
DOI
ScienceOn
|
12 |
Zitvogel L, Kepp O, Senovilla L, Menger L, Chaput N, Kroemer G: Immunogenic tumor cell death for optimal anticancer therapy: the calreticulin exposure pathway. Clin Cancer Res 16;3100-3104, 2010.
DOI
|
13 |
Nowak AK, Robinson BW, Lake RA: Gemcitabine exerts a selective effect on the humoral immune response: implications for combination chemo-immunotherapy. Cancer Res 62;2353-2358, 2002.
|
14 |
Suzuki E, Kapoor V, Jassar AS, Kaiser LR, Albelda SM: Gemcitabine selectively eliminates splenic Gr-1+/CD11b+ myeloid suppressor cells in tumor-bearing animals and enhances antitumor immune activity. Clin Cancer Res 11;6713- 6721, 2005.
DOI
ScienceOn
|
15 |
Galon J, Costes A, Sanchez-Cabo F, Kirilovsky A, Mlecnik B, Lagorce-Pag s C, Tosolini M, Camus M, Berger A, Wind P, Zinzindohou F, Bruneval P, Cugnenc PH, Trajanoski Z, Fridman WH, Pagès F: Type, density, and location of immune cells within human colorectal tumors predict clinical outcome. Science 313;1960-1964, 2006.
DOI
ScienceOn
|
16 |
Apetoh L, Mignot G, Panaretakis T, Kroemer G, Zitvogel L: Immunogenicity of anthracyclines: moving towards more personalized medicine. Trends Mol Med 14;141-151, 2008.
DOI
ScienceOn
|
17 |
Zitvogel L, Apetoh L, Ghiringhelli F, Kroemer G: Immunological aspects of cancer chemotherapy. Nat Rev Immunol 8;59-73, 2008.
DOI
ScienceOn
|
18 |
Obeid M, Panaretakis T, Tesniere A, Joza N, Tufi R, Apetoh L, Ghiringhelli F, Zitvogel L, Kroemer G: Leveraging the immune system during chemotherapy: moving calreticulin to the cell surface converts apoptotic death from "silent" to immunogenic. Cancer Res 67;7941-7944, 2007.
DOI
ScienceOn
|
19 |
Machiels JP, Reilly RT, Emens LA, Ercolini AM, Lei RY, Weintraub D, Okoye FI, Jaffee EM: Cyclophosphamide, doxorubicin, and paclitaxel enhance the antitumor immune response of granulocyte/macrophage-colony stimulating factor-secreting whole-cell vaccines in HER-2/neu tolerized mice. Cancer Res 61;3689-3697, 2001.
|